Desensitization with plasma exchange in a patient with human leukocyte antigen donor-specific antibodies before T-cell-replete haploidentical transplantation.
Bramanti S
Transfusion. 2016 Mar 28;56(5):1096-1100. doi: 10.1111/trf.13523
Tacrolimus compared with cyclosporine A after haploidentical T-cell replete transplantation with post-infusion cyclophosphamide.
Castagna L
Bone Marrow Transplant. 51(3):470. doi: 10.1038/bmt.2015.327
T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromes.
Devillier R
Bone Marrow Transplant. 2015 Nov 9;51(2):194-8. doi: 10.1038/bmt.2015.270
Tandem autologous-allogeneic stem cell transplantation as a feasible and effective procedure in high-risk lymphoma patients.
Crocchiolo R
Haematologica. 2015 Jul 23;100(10):e423-7. doi: 10.3324/haematol.2015.129452
Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Italian centers.
Carlo-Stella C
Oncologist. 2015 Feb 10;20(3):323-8. doi: 10.1634/theoncologist.2014-0420
Infections after T-replete haploidentical transplantation and high-dose cyclophosphamide as graft-versus-host disease prophylaxis.
Crocchiolo R
Transpl Infect Dis. 17(2):242-9. doi: 10.1111/tid.12365
High-dose melphalan with autologous stem cell support in refractory Hodgkin lymphoma patients as a bridge to second transplant.
Castagna L
Bone Marrow Transplant. 2015 Jan 26;50(4):499-504. doi: 10.1038/bmt.2014.304
Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells.
Reichel J
Blood. 2014 Dec 8;125(7):1061-72. doi: 10.1182/blood-2014-11-610436
High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors: mature results of an Italian randomized phase II study.
Necchi A
Ann Oncol. 2014 Oct 24;26(1):167-172. doi: 10.1093/annonc/mdu485
YM155 sensitizes triple-negative breast cancer to membrane-bound TRAIL through p38 MAPK- and CHOP-mediated DR5 upregulation.
Pennati M
Int J Cancer. 2014 Jun 5;136(2):299-309. doi: 10.1002/ijc.28993